VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients

被引:18
作者
Horie, Takahiro [1 ]
Ono, Koh [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, 54 Kawahara Cho,Sakyo Ku, Kyoto 6068507, Japan
关键词
D O I
10.1093/ehjcvp/pvad103
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:89 / 90
页数:2
相关论文
共 5 条
[1]   Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors [J].
Anzalone, Andrew V. ;
Koblan, Luke W. ;
Liu, David R. .
NATURE BIOTECHNOLOGY, 2020, 38 (07) :824-844
[2]   Programmable base editing of A.T to G.C in genomic DNA without DNA cleavage [J].
Gaudelli, Nicole M. ;
Komor, Alexis C. ;
Rees, Holly A. ;
Packer, Michael S. ;
Badran, Ahmed H. ;
Bryson, David I. ;
Liu, David R. .
NATURE, 2017, 551 (7681) :464-+
[3]   Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models [J].
Lee, Richard G. ;
Mazzola, Anne Marie ;
Braun, Maurine C. ;
Platt, Colin ;
Vafai, Scott B. ;
Kathiresan, Sekar ;
Rohde, Ellen ;
Bellinger, Andrew M. ;
Khera, Amit, V .
CIRCULATION, 2023, 147 (03) :242-253
[4]   Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol [J].
Ray, Kausik K. ;
Wright, R. Scott ;
Kallend, David ;
Koenig, Wolfgang ;
Leiter, Lawrence A. ;
Raal, Frederick J. ;
Bisch, Jenna A. ;
Richardson, Tara ;
Jaros, Mark ;
Wijngaard, Peter L. J. ;
Kastelein, John J. P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (16) :1507-1519
[5]  
Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.4997/JRCPE.2017.212, 10.1056/NEJMoa1615664]